6.74
前日終値:
$6.71
開ける:
$6.62
24時間の取引高:
2.20M
Relative Volume:
1.65
時価総額:
$437.37M
収益:
$65,400
当期純損益:
$-46.34M
株価収益率:
-7.3261
EPS:
-0.92
ネットキャッシュフロー:
$-38.74M
1週間 パフォーマンス:
-38.22%
1か月 パフォーマンス:
-34.24%
6か月 パフォーマンス:
-16.27%
1年 パフォーマンス:
+58.96%
CorMedix Inc Stock (CRMD) Company Profile
名前
CorMedix Inc
セクター
電話
908-517-9500
住所
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
CRMD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CRMD
CorMedix Inc
|
6.74 | 437.37M | 65,400 | -46.34M | -38.74M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-07 | 開始されました | Leerink Partners | Outperform |
2025-01-13 | 開始されました | D. Boral Capital | Buy |
2024-08-26 | 開始されました | Rodman & Renshaw | Buy |
2023-08-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-02-17 | 開始されました | Needham | Buy |
2020-09-29 | 開始されました | JMP Securities | Mkt Outperform |
2020-09-21 | 開始されました | Truist | Buy |
2019-12-18 | 開始されました | B. Riley FBR | Buy |
2019-03-26 | 繰り返されました | H.C. Wainwright | Buy |
2018-12-06 | 開始されました | ROTH Capital | Buy |
2017-09-25 | 繰り返されました | H.C. Wainwright | Buy |
2017-08-10 | 繰り返されました | Rodman & Renshaw | Buy |
2017-05-05 | 繰り返されました | Rodman & Renshaw | Buy |
2016-11-11 | 繰り返されました | FBR & Co. | Outperform |
2016-03-17 | 繰り返されました | FBR Capital | Outperform |
2016-03-03 | 開始されました | FBR Capital | Outperform |
2015-11-16 | 繰り返されました | ROTH Capital | Neutral |
2015-10-29 | 繰り返されました | ROTH Capital | Neutral |
2015-05-06 | ダウングレード | ROTH Capital | Buy → Neutral |
2014-12-08 | 繰り返されました | ROTH Capital | Buy |
2011-10-03 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
CorMedix Inc (CRMD) 最新ニュース
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix Stock: A Fair-Priced Biotech Company With A Bright Future (NASDAQ:CRMD) - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - Simply Wall St
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.com
Long Term Trading Analysis for (CRMD) - Stock Traders Daily
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
CorMedix: Q4 Earnings Snapshot - mySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com South Africa
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - Mitrade
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - Marketscreener.com
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia
CorMedix shares tumble after order delay By Investing.com - Investing.com Canada
CorMedix shares tumble after order delay - Investing.com
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges By Investing.com - Investing.com South Africa
CorMedix Dives on Results - Baystreet.ca
CorMedix Inc reports results for the quarter ended December 31Earnings Summary - TradingView
CorMedix Q4 Swings To Profit, Stock Down In Pre-market - Nasdaq
CorMedix Inc. Provides Preliminary Earnings Guidance for the First Half of 2025 - Marketscreener.com
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
CORMEDIX Earnings Results: $CRMD Reports Quarterly Earnings - Nasdaq
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
CorMedix Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
CorMedix Hits Major Milestone: First-Ever Profitable Quarter Signals Strong Growth Ahead - StockTitan
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
CORMEDIX Earnings Preview: Recent $CRMD Insider Trading, Hedge Fund Activity, and More - Nasdaq
CorMedix Inc expected to post earnings of 14 cents a shareEarnings Preview - TradingView
CRMD INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CorMedix Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 20 Deadline in Securities Class Action – CRMD - Business Wire
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025 - The Manila Times
CorMedix Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
Cormedix Inc. To Report Fourth Quarter And Full Year 2024 Financial Results And Provide A Corporate Update On March 25, 2025 - MENAFN.COM
(CRMD) Investment Report - Stock Traders Daily
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India
Beeline Holdings Appoints Industry Veteran David Kittle as Special Advisor - The Globe and Mail
Energy Products and Services Stocks Q4 Recap: Benchmarking MDU Resources (NYSE:MDU) - The Globe and Mail
CorMedix Inc (CRMD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):